Join Transform 2021 this July 12-16. Register for the AI event of the year. HOUSTON–(BUSINESS WIRE)–May 3, 2021– ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead compound IM156, […]